OPRX

Business Context and Reporting Period

Company: OptimizeRx Corporation (Nevada corporation with a wholly-owned Michigan subsidiary).
Reporting Period: Fiscal year ended December 31, 2008.
Business Model: A development-stage company operating a patient savings portal (OPTIMIZERx.com) and advertising platforms (OFFERx and ADHERxE) connecting patients, pharmacies, and pharmaceutical manufacturers. The company focuses on helping patients manage healthcare costs while providing marketing services to the pharmaceutical industry.
Corporate Status: Completed a reverse merger with RFID Ltd. in April 2008 and a migratory merger to Nevada in September 2008. Classified as a "smaller reporting company."

Key Financial Metrics

Cash Flow Summary (2008):
- Operating Activities: Used $919,402 (primarily due to net loss, offset by non-cash stock-based compensation).
- Investing Activities: Used $10,621.
- Financing Activities: Provided $3,297,250 (driven by $2,985,000 net proceeds from preferred stock and $636,000 from common stock).

Material Changes vs. Prior Period

• Revenue Decline: Gross revenues decreased 16.6% to $83,686 from $100,318 in 2007.
• Expense Surge: Operating expenses increased 249% to $1.59 million. Key drivers included advertising ($380k), stock-based compensation ($333k), and consulting fees ($323k).
• Non-Cash Charges: Other expenses skyrocketed to $2.74 million, primarily due to $2.745 million in warrant-based compensation expenses related to financing activities.
• Liquidity Improvement: Cash balances increased from $135k to $2.5 million following a significant capital raise in September 2008.
• Debt Reduction: Total liabilities decreased as the company repaid $643,750 in notes payable to related parties using proceeds from the preferred stock offering.

Guidance, Outlook, and Risks

Management Commentary & Outlook:
Management anticipates aggressive growth in 2009, citing the acquisition of 300,000 new members in the first two months of 2009 and the launch of national cable advertising. The estimated monthly cash burn rate is $57,000 to $90,000 (excluding variable marketing spend). Management believes current cash reserves are sufficient to fund operations for the next twelve months.

Risks and Contingencies:
- Internal Controls: Management identified a material weakness in internal controls over financial reporting due to a lack of segregation of duties (only one employee overseeing bank reconciliations and payables). Remediation is planned for 2009.
- Regulatory: Significant exposure to federal and state healthcare fraud and abuse laws (Anti-Kickback Statute, False Claims Act) and HIPAA privacy regulations.
- Competition: Highly competitive market dominated by larger entities (WebMD, McKesson, Drugs.com).
- Capital Dependence: As a development-stage company, the firm relies on continued financing to sustain operations and marketing campaigns.

Investor Verification Checklist

• Capital Raise Terms: Verify the conversion terms and dividend obligations of the Series A Preferred Stock issued to Vicis Capital Master Fund ($3.5M gross proceeds, 10% cumulative dividend, convertible to 3.5M common shares).
• Warrant Liability: Confirm the valuation methodology and impact of the $14.16M in warrants issued to preferred shareholders and the $2.74M in warrants issued for services.
• Revenue Sustainability: Assess the source and sustainability of the $83k in revenue, given the heavy reliance on future advertising sales which have not yet materialized at scale.
• Internal Control Remediation: Monitor the implementation of checks and balances in financial reporting as promised for 2009.
• Related Party Transactions: Review the repayment of related party notes and the ongoing compensation arrangements with officers (e.g., David Harrell).